Group Highlights
Group revenue increased by 9% to $1,489 million, driven by strong growth in Injectables
Profit attributable to shareholders increased by 31% to $278 million. On an adjusted basis, profit attributable to shareholders rose 9% to $299 million
Basic EPS increased 30% to 140.4 cents per share and adjusted EPS increased by 9% to 151.0 cents per share
Net cash flow from operating activities increased by $88 million to $425 million
Proposed final dividend of 15.0 cents per share (22.0 cents per share for the full year), plus a special dividend of 6.0 cents per share (10.0 cents per share for the full year), making a total combined dividend for the year of 32.0 cents per share
Expecting 2015 Group revenue growth of around 6% in constant currency
Adverse exchange rate movements since the beginning of 2015could impact full year Group revenue by around 3%, or
$45 million, should current exchange rates prevail
